Effect of specific immunotherapy on serum levels of tumor necrosis factor alpha in asthmatic children

Allergy and Asthma Proceedings

Volumn 29, Issue 3, 2008, Pages 274-279

  Jerzyńska, Joanna ^a   Stelmach, Włodzimierz ^b   Majak, Pawel ^a   Brzozowska, Agnieszka ^a   Sobocińska, Agnieszka ^a   Stelmach, Iwona ^a,b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b N Copernicus Hospital   (Poland)

Author keywords

Allergy; Asthma; Children; Cytokines; IL 1beta; IL 6; Immunotherapy; Mechanisms; Subcutaneous immunotherapy; TNF alpha

Indexed keywords

HOUSE DUST ALLERGEN; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; ASTHMA; BLOOD; BRONCHUS HYPERREACTIVITY; CHILD; DESENSITIZATION; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMAN; IMMUNOLOGY; INHALATION TEST; MALE; PROSPECTIVE STUDY; SPIROMETRY; TREATMENT OUTCOME;

ANTIGENS, DERMATOPHAGOIDES; ASTHMA; BRONCHIAL HYPERREACTIVITY; BRONCHIAL PROVOCATION TESTS; CHILD; DESENSITIZATION, IMMUNOLOGIC; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPIROMETRY; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 46649094570     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: 10.2500/aap.2008.29.3112     Document Type: Article

References (22)

1. Sinclair H, Allwright S, and Prichard J. Secular trends in mortality from asthma in children and young adults: Republic of Ireland, 1970-91. Ir J Med Sci 164:45-47, 1995.
2. Ariano R, Berto P, Tracci D, et al. Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma. Allergy Asthma Proc 27:159-163, 2006.
3. Wilcock LK, Francis JN, and Durham SR. IgE-facilitated antigen presentation: Role in allergy and the influence of allergen immunotherapy. Immunol Allergy Clin North Am 26:333-347, 2006.
4. DuBuske LM. Mediator assays and modulation of inflammation in asthma: Introduction. Allergy 16:55-58, 1995.
5. Durham SR, Till SJ, and Corrigan CJ. T lymphocytes in asthma: Bronchial versus peripheral responses. J Allergy Clin Immunol 106:S221-S226, 2000.
6. Kay AB. Immunomodulation in asthma: Mechanisms and possible pitfalls. Curr Opin Pharmacol 3:220-226, 2003.
7. Van Bever HP, Vereecke IF, Bridts CH, et al. Comparison between the in vitro cytokine production of mononuclear cells of young asthmatics with and without immunotherapy (IL). Clin Exp Allergy 28:943-949, 1998.
8. Durham SR, Ying S, Varney VA, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-γ. J Allergy Clin Immunol 97:1356-1365, 1996.
9. The global initiative for asthma. The National Heart, Lung, and Blood Institute and The World Health Organization. Available on-line at www.ginasthma.com; last accessed April, 2008.
10. Crapo RO, Hankinson JL, and Irvin C. Standarization of spirometry. Am J Respir Crit Care Med 152:1107-1136, 1995.
11. Cockroft DW, Murdock KY, and Mink JT. Determination of histamine PC20. Chest 54:505-506, 1983.
12. Gosset P, Tsicopoulos A, Wallaert B, et al. Increased secretion of tumor necrosis alpha and inlerleukin-6 by alveolar macrophages consecutive to the development of the late asthmatic reaction. J Allergy Clin Immunol 88:561-571, 1991.
13. Berry MA, Hargadon B, Shelley M, et al. Evidence of a role for tumor necrosis factor in refractory asthma. N Engl J Med 354:697-708, 2006.
14. Erin EM, Leaker BR, Nicholson GC, et al. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med 174:753-762, 2006.
15. Erzurum SC. Inhibition of tumor necrosis factor for refractory asthma. N Engl J Med 354:754-758, 2006.
16. Nagata M, Saito K, Kikuchi I, et al. Immunotherapy attenuates eosinophil transendothelial migration induced by the supernatants of antygen-stimulated mononuclear cells from atopic asthmatics. Int Arch Allergy Immnunol 134:21-24, 2004.
17. De Amici M, Puggioni F, Cassali L, et al. Variations in serum levels of interleukin (IL)-1 beta, IL-2, IL-6, and tumor necrosis factor-alpha during specific immunotherapy. Ann Allergy Asthma Immunol 86:311-313, 2001.
18. Tanaka A, Ohashi Y, Kakinoki Y, et al. Immunotherapy suppresses both Th1 and Th2 responses by allergen stimulation, but suppression of the Th2 response is a more important mechanism related to the clinical efficacy of immunotherapy for perennial allergic rhinitis. Scand J Immunol 48:201-211, 1998.
19. Bousquet J, Corrigan CJ, and Venge P. Peripheral blood markers: Evaluation and inflammation in asthma. Eur Respir J 26:42-48, 1998.
20. Stelmach I, Jerzyńska J, and Kuna P. Markers of allergic inflammation in peripheral blood of children with asthma after treatment with inhaled triamcinolone acetonide. Ann Allergy Asthma Immunol 87:319-326, 2001.
21. Dinakar C, Van Osdol TJ, Barnes CS, et al. Changes in exhaled nitric oxide levels with immunotherapy. Allergy Asthma Proc 27:140-144, 2006.
22. Finegold I. Allergen immunotherapy: Present and future. Allergy Asthma Proc 28:44-49, 2007.